Everolimus

Generic Name
Everolimus
Brand Names
Afinitor, Votubia, Zortress
Drug Type
Small Molecule
Chemical Formula
C53H83NO14
CAS Number
159351-69-6
Unique Ingredient Identifier
9HW64Q8G6G
Background

Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.

Indication

Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole.
...

Associated Conditions
Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Progressive Neuroendocrine Tumors of pancreatic origin, Renal angiomyolipoma, tuberous sclerosis complex, Subependymal giant cell astrocytoma, tuberous sclerosis complex, Waldenstrom's Macroglobulinemia Refractory, Advanced Carcinoid tumor, Locally advanced Progressive Neuroendocrine Tumors of gastrointestinal origin, Locally advanced lung origin Progressive Neuroendocrine Tumors, Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors, Metastatic lung origin Progressive Neuroendocrine Tumors, Refractory Advanced Renal Cell Carcinoma, Refractory, advanced Breast cancer, Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors, Unresectable lung origin Progressive Neuroendocrine Tumors
Associated Therapies
-
Clinical Trials
Related News

The Efficacy of Everolimus With Reduced-dose Tacrolimus Versus Reduced-dose Tacrolimus in Treatment of BK Virus Infection in Kidney Transplantation Recipient

First Posted Date
2020-09-09
Last Posted Date
2024-01-05
Lead Sponsor
King Chulalongkorn Memorial Hospital
Target Recruit Count
50
Registration Number
NCT04542733
Locations
🇹🇭

King Chulalongkorn Memorial Hospital, Bangkok, Thailand

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

First Posted Date
2020-07-24
Last Posted Date
2024-04-17
Lead Sponsor
University of California, San Francisco
Target Recruit Count
50
Registration Number
NCT04485559
Locations
🇺🇸

Children's Minnesota, Minneapolis, Minnesota, United States

🇺🇸

Children's Hospital Los Angeles, Los Angeles, California, United States

🇺🇸

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

and more 14 locations

Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer

First Posted Date
2020-04-21
Last Posted Date
2022-07-26
Lead Sponsor
Fudan University
Target Recruit Count
319
Registration Number
NCT04355858
Locations
🇨🇳

Cancer Hospital Affiliated to Fudan University, Shanghai, Shanghai, China

Cemiplimab in AlloSCT/SOT Recipients With CSCC

First Posted Date
2020-04-08
Last Posted Date
2024-06-12
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
12
Registration Number
NCT04339062
Locations
🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

Everolimus Plus Mycophenolic Acid for Kidney Preservation in Liver Transplant Recipients With Impaired Kidney Function

Phase 3
Terminated
Conditions
Kidney Failure
Interventions
Drug: Tacrolimus
Drug: Everolimus
First Posted Date
2020-02-06
Last Posted Date
2023-05-24
Lead Sponsor
Indiana University
Target Recruit Count
4
Registration Number
NCT04258423
Locations
🇺🇸

Indiana University, Indianapolis, Indiana, United States

Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

First Posted Date
2019-12-13
Last Posted Date
2024-10-15
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
20
Registration Number
NCT04199026
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

Phase 3
Active, not recruiting
Conditions
Carcinoma, Renal Cell
Interventions
Drug: Belzutifan
Drug: Everolimus
First Posted Date
2019-12-12
Last Posted Date
2024-11-18
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
755
Registration Number
NCT04195750
Locations
🇺🇸

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 1514), Baltimore, Maryland, United States

🇺🇸

The University of Chicago Medical Center ( Site 1539), Chicago, Illinois, United States

🇺🇸

Cleveland Clinic ( Site 1504), Cleveland, Ohio, United States

and more 169 locations

A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer

First Posted Date
2019-12-06
Last Posted Date
2024-08-28
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
500
Registration Number
NCT04188548
Locations
🇺🇸

Winship Cancer Center Emory University, Atlanta, Georgia, United States

🇺🇸

Johns Hopkins University, Baltimore, Maryland, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

and more 69 locations

A MolEcularly Guided Anti-Cancer Drug Off-Label Trial

Phase 2
Active, not recruiting
Conditions
Solid Tumor
Interventions
Drug: Everolimus
Drug: Atezolizumab
Drug: Niraparib
Drug: Cobimetinib
First Posted Date
2019-12-04
Last Posted Date
2024-08-22
Lead Sponsor
Uppsala University Hospital
Target Recruit Count
167
Registration Number
NCT04185831
Locations
🇸🇪

Skane University Hospital, Lund, Sweden

🇸🇪

Uppsala University Hospital, Uppsala, Sweden

🇸🇪

Sahlgrenska University Hospital, Gothenburg, Sweden

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

First Posted Date
2019-12-04
Last Posted Date
2024-11-28
Lead Sponsor
Amgen
Target Recruit Count
1200
Registration Number
NCT04185883
Locations
🇺🇸

Henry Ford Cancer Detroit (Brigitte Harris Cancer Pavilion), Detroit, Michigan, United States

🇺🇸

Arizona Oncology Associates Professional Corporation, Tucson, Arizona, United States

🇺🇸

City of Hope National Medical Center, Duarte, California, United States

and more 87 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy